# Viemed Healthcare, Inc.: Form 10-Q for the period ended Jun 30, 2021

- Company: [Viemed Healthcare, Inc.](/companies/vmd.md) (CIK 1729149)
- Form: 10-Q
- Filed: 2021-08-03
- Accepted by EDGAR: Aug 2, 2021, 17:33 ET
- Period: 2021-06-30
- Accession: 0001729149-21-000106
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1729149/000172914921000106/vmd-20210630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1729149/000172914921000106/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-04-01 to 2021-06-30 | $27.4m | us-gaap:Revenues |
| Revenue | 6 months, 2021-01-01 to 2021-06-30 | $55.8m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2021-04-01 to 2021-06-30 | $9.8m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2021-01-01 to 2021-06-30 | $20.4m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2021-04-01 to 2021-06-30 | $17.6m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2021-01-01 to 2021-06-30 | $35.4m | us-gaap:GrossProfit |
| Research and development | 3 months, 2021-04-01 to 2021-06-30 | $583.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2021-01-01 to 2021-06-30 | $922.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2021-04-01 to 2021-06-30 | $12.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2021-01-01 to 2021-06-30 | $27.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2021-04-01 to 2021-06-30 | $2.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2021-01-01 to 2021-06-30 | $4.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2021-04-01 to 2021-06-30 | $1.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2021-01-01 to 2021-06-30 | $1.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-04-01 to 2021-06-30 | $1.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2021-01-01 to 2021-06-30 | $3.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-04-01 to 2021-06-30 | $0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2021-01-01 to 2021-06-30 | $0.08 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-04-01 to 2021-06-30 | $0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2021-01-01 to 2021-06-30 | $0.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-04-01 to 2021-06-30 | 41,028,742 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2021-01-01 to 2021-06-30 | 40,849,311 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2021-01-01 to 2021-06-30 | $8.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2021-01-01 to 2021-06-30 | $5.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months, 2021-01-01 to 2021-06-30 | $1.4m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2021-06-30 | $31.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-06-30 | $47.0m | us-gaap:AssetsCurrent |
| Total assets | at 2021-06-30 | $111.0m | us-gaap:Assets |
| Current liabilities | at 2021-06-30 | $18.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-06-30 | $24.8m | us-gaap:Liabilities |
| Long-term debt | at 2021-06-30 | $4.8m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2021-06-30 | $1.9m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2021-06-30 | $86.3m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1729149/000172914921000106/vmd-20210630.htm

Filed Aug 3, 2021.
Source: SEC EDGAR, the filing index for accession 0001729149-21-000106. Last ingested by Listed: Nov 4, 2026, 19:03 ET. No prices; not investment advice.
